SafeBeat Rx Raises $994K in Grant Funding to Revolutionize Mobile Cardiac Care

SafeBeat Rx (YC S21) is excited to announce that it has successfully raised $994,000 in funding to accelerate its mission of transforming cardiac care through advanced technology. The company, which specializes in producing software that powers cardiac therapeutics monitoring directly from your phone, is at the forefront of merging medical expertise with cutting-edge technology. With a multidisciplinary team that includes heart rhythm physicians, big data telehealth specialists, artificial intelligence-trained software engineers, clinical trial experts, and professionals well-versed in regulation and reimbursement, SafeBeat Rx is uniquely positioned to address the challenges of modern cardiac care. This funding milestone represents more than just capital—it is a vital endorsement of SafeBeat Rx’s innovative approach and a significant step toward expanding the reach and impact of its monitoring solutions. The newly raised funds will be directed toward further development and refinement of the company’s platform, supporting enhancements in user interface, data security, and predictive analytics. By leveraging these resources, SafeBeat Rx will be able to extend its technological capabilities to more comprehensively monitor heart rhythm abnormalities and provide actionable insights to both healthcare providers and patients. The investment also positions the company to scale its operations, ensuring that its state-of-the-art cardiac monitoring tools can be implemented more broadly within telehealth environments. In doing so, SafeBeat Rx continues to uphold its commitment to using engineering innovation to bring significant improvements to cardiac therapeutics and ultimately save lives. This funding not only fortifies the company’s current projects but also paves the way for future advancements in the field of cardiac care management.